{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:46:31Z","timestamp":1793879191433,"version":"4.7.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To evaluate the 12-month safety and effectiveness of transcervical ablation for the treatment of symptomatic uterine leiomyomas.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>In this prospective, multicenter, single-arm interventional trial, transcervical ablation was performed on 1\u201310 leiomyomas per patient with leiomyoma diameters ranging from 1 to 5 cm. Treated leiomyomas included all nonpedunculated types. Coprimary endpoints assessed at 12 months were reduction in menstrual blood loss and absence of surgical reintervention. Additional assessments included symptom severity, quality of life, patient satisfaction, reductions in uterine and leiomyoma volumes, and safety.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>One hundred forty-seven patients were enrolled and treated in the United States and Mexico. The study met its coprimary endpoints at 12 months (N=143; full analysis set), because 64.8% of patients (95% CI 56.3\u201372.6%) experienced 50% or greater reduction in menstrual bleeding and 99.3% of patients (95% CI 95.1\u201399.9%) were free from surgical reintervention. The mean pictorial blood loss assessment chart score decreased by 38.9%, 48.4%, and 51.1% at 3, 6, and 12 months, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001), and 95.1% of patients experienced a reduction in menstrual bleeding at 12 months. There were significant mean improvements in symptom severity and health-related quality of life of 32.1 points and 43.7 points, respectively, at 12 months (all <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001). Mean maximal leiomyoma volume reduction per patient was 62.4% (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001). More than half of patients returned to normal activity within 1 day, 96.3% of patients reported symptom improvement at 12 months, and 97% expressed satisfaction with the treatment at 12 months. There were no device-related adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Transcervical ablation was associated with a significant reduction in leiomyoma symptoms with no device-related adverse events and a low surgical reintervention rate through 12 months, demonstrating its potential to safely and effectively treat all nonpedunculated leiomyoma types through a uterus-conserving, incisionless approach.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n            <jats:p>\n                                 ClinicalTrials.gov, NCT02228174.<\/jats:p>\n            <jats:p>Funding Source: Supported by Gynesonics, Inc.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000003032","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T21:48:29Z","timestamp":1544132909000},"page":"13-22","source":"Crossref","is-referenced-by-count":57,"title":["Ultrasound-Guided Transcervical Ablation of Uterine Leiomyomas"],"prefix":"10.1097","volume":"133","author":[{"given":"Scott","family":"Chudnoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Guido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Mihalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Gerardo","family":"Garza-Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence","volume":"188","author":"Baird","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"319 e1","DOI":"10.1016\/j.ajog.2013.07.017","article-title":"The impact of uterine leiomyomata: a national survey of affected women","volume":"209","author":"Borah","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta12050","article-title":"A multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids. The HOPEFUL study","volume":"12","author":"Hirst","year":"2008","journal-title":"Health Technol Assess"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10397-010-0655-3","article-title":"Transcervical, intrauterine ultrasound-guided radiofrequency ablation of uterine fibroids with the VizAblate System: safety, tolerability, and ablation results in a closed abdomen setting","volume":"8","author":"Garza-Leal","year":"2011","journal-title":"Gynecol Surg"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s00464-007-9307-8","article-title":"Midterm outcome of radiofrequency thermal ablation for symptomatic uterine myomas","volume":"21","author":"Ghezzi","year":"2007","journal-title":"Surg Endosc"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1055\/s-0035-1545931","article-title":"Radiofrequency volumetric thermal ablation of fibroids and laparoscopic myomectomy: long-term follow-up from a randomized trial","volume":"75","author":"Hahn","year":"2015","journal-title":"Geburtshilfe Frauenheilkund"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jmig.2017.05.021","article-title":"Radiofrequency thermal ablation for uterine fibroids: long-term clinical outcomes and reinterventions","volume":"24","author":"Iversen","year":"2017","journal-title":"J Minim Invasive Gynecol"},{"key":"R8-20230711","doi-asserted-by":"crossref","first-page":"194839","DOI":"10.1155\/2012\/194839","article-title":"Radiofrequency ablation for treatment of symptomatic uterine fibroids","volume":"2012","author":"Jones","year":"2012","journal-title":"Obstet Gynecol Int"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s13669-016-0183-x","article-title":"Radiofrequency ablation of uterine fibroids: a review","volume":"5","author":"Lee","year":"2016","journal-title":"Curr Obstet Gynecol Rep"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2214\/AJR.07.2184","article-title":"Percutaneous sonographically guided radiofrequency ablation of medium-sized fibroids: feasibility study","volume":"189","author":"Recaldini","year":"2007","journal-title":"AJR Am J Roentgenol"},{"key":"R11-20230711","first-page":"901","article-title":"Potential of minimally invasive procedures in the treatment of uterine fibroids: a focus on magnetic resonance-guided focused ultrasound therapy","volume":"7","author":"Fischer","year":"2015","journal-title":"Int J Womens Health"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2214\/AJR.13.11446","article-title":"MRI-guided focused ultrasound surgery for uterine fibroid treatment: a cost-effectiveness analysis","volume":"203","author":"Kong","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"R13-20230711","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/01.AOG.0000275283.39475.f6","article-title":"Sustained relief of leiomyoma symptoms by using focused ultrasound surgery","volume":"110","author":"Stewart","year":"2007","journal-title":"Obstet Gynecol"},{"key":"R14-20230711","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.fertnstert.2005.04.072","article-title":"Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids","volume":"85","author":"Stewart","year":"2006","journal-title":"Fertil Steril"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10397-015-0915-3","article-title":"The FAST-EU trial: 12-month clinical outcomes of women after intrauterine sonography-guided transcervical radiofrequency ablation of uterine fibroids","volume":"13","author":"Brolmann","year":"2016","journal-title":"Gynecol Surg"},{"key":"R16-20230711","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s13669-017-0194-2","article-title":"A new paradigm for uterine fibroid treatment: transcervical, intrauterine sonography-guided radiofrequency ablation of uterine fibroids with the Sonata System","volume":"6","author":"Toub","year":"2017","journal-title":"Curr Obstet Gynecol Rep"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejogrb.2018.03.053","article-title":"Improvement in health utility after transcervical radiofrequency ablation of uterine fibroids with the sonata system: health utility after radiofrequency ablation","volume":"224","author":"Huirne","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R18-20230711","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/0029-7844(95)00062-V","article-title":"A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss","volume":"85","author":"Janssen","year":"1995","journal-title":"Obstet Gynecol"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10397-015-0893-5","article-title":"Pictorial blood loss assessment chart for quantification of menstrual blood loss: a systematic review","volume":"12","author":"El-Nashar","year":"2015","journal-title":"Gynecol Surg"},{"key":"R20-20230711","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1471-0528.1990.tb16249.x","article-title":"Assessment of menstrual blood loss using a pictorial chart","volume":"97","author":"Higham","year":"1990","journal-title":"Br J Obstet Gynaecol"},{"key":"R21-20230711","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/MLR.0b013e3181c162a2","article-title":"Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments","volume":"48","author":"Luo","year":"2010","journal-title":"Med Care"},{"key":"R22-20230711","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10397-014-0873-1","article-title":"Transcervical, intrauterine ultrasound-guided radiofrequency ablation of uterine fibroids with the VizAblate\u00ae System: three- and six-month endpoint results from the FAST-EU study","volume":"12","author":"Bongers","year":"2015","journal-title":"Gynecol Surg"},{"key":"R23-20230711","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1055\/s-0037-1607264","article-title":"Uterine fibroids: burden and unmet medical need","volume":"35","author":"Al-Hendy","year":"2017","journal-title":"Semin Reprod Med"},{"key":"R24-20230711","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jmig.2013.05.007","article-title":"Does menstrual bleeding decrease after ablation of intramural myomas? A retrospective study","volume":"20","author":"Galen","year":"2013","journal-title":"J Minim Invasive Gynecol"},{"key":"R25-20230711","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pupt.2014.01.005","article-title":"Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view","volume":"27","author":"Saturni","year":"2014","journal-title":"Pulm Pharmacol Ther"},{"key":"R26-20230711","doi-asserted-by":"crossref","first-page":"199","DOI":"10.11613\/BM.2014.022","article-title":"Observational and interventional study design types; an overview","volume":"24","author":"Thiese","year":"2014","journal-title":"Biochem Med (Zagreb)"},{"key":"R27-20230711","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1471-0528.2011.02952.x","article-title":"Randomised comparison of uterine artery embolisation (UAE) with surgical treatment in patients with symptomatic uterine fibroids (REST trial): 5-year results","volume":"118","author":"Moss","year":"2011","journal-title":"BJOG"},{"key":"R28-20230711","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/AOG.0b013e31828b7962","article-title":"Outpatient procedure for the treatment and relief of symptomatic uterine myomas","volume":"121","author":"Chudnoff","year":"2013","journal-title":"Obstet Gynecol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006250-201901000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T19:35:55Z","timestamp":1689104155000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201901000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000003032","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}